New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients

Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial

Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC